ERα is a potent driver of the proliferation and progression of ER-positive breast cancer, and, thus, this lower expression of ESR1/ERα may lead to a less aggressive tumor progression and, hence, a favorable prognosis. The gene discussed is ESR1; the disease is neoplasm.